Compounding Supply Costs: What to Expect
A practical, data-backed guide to controlling costs and automating expense workflows.
The rules governing compounding supply costs in the US pharmacy industry are complex and constantly evolving. This license allows pharmacies to compound medications for patients with severe medical conditions, but it also comes with specific rules and limits on supply costs. For the bigger picture, see our guide to independent pharmacies expense management software. For a complete overview, see our expense management guide.
Potential Pitfalls
- In the United States, the FDA requires all active pharmaceutical ingredients (APIs) used in compounding to be sourced from FDA-registered suppliers. This ensures that only approved and compliant ingredients are used in compounded medications.
- The FDA has implemented rules to prevent the sale of compounded medications that contain unapproved or misbranded ingredients. These rules include requirements for labeling, packaging, and testing.
- The FDA has established guidelines for the storage and handling of compounded medications to prevent contamination and ensure patient safety.
- Compounded medications can be subject to recall if they contain unapproved or misbranded ingredients, or if they are contaminated with foreign substances.
- The FDA has implemented a system for tracking and monitoring compounded medications, including the use of the National Drug Product Inventory (NDPI) database.
- Compounding pharmacies must also comply with the FDA's regulations regarding the labeling and packaging of compounded medications, including the requirement for a compounding statement of ingredients.
Keeping this simple: Incurdesk turns submitted expenses into clean expense reports. It is built for small independent pharmacy teams. Try it free.
Current Developments and Future Outlook
The regulatory landscape for compounded medications in the US is constantly evolving. Currently, the Current Flexibilities for prescribing controlled substances via telemedicine are extended through December 31, 2026.
In addition, the FDA is anticipated to issue new regulations for compounding supply costs, which will require pharmacies to provide more detailed information about their compounding processes and facilities. This is in response to the growing need for transparency and accountability in the compounding industry.
Pharmacies that compound based on patient-specific prescriptions are primarily regulated by state boards of pharmacy.
As the regulatory landscape continues to shift, pharmacies must stay informed about the latest developments and requirements. It is essential to review the DEA's permanent telemedicine regulations and the FDA's new regulations for compounding supply costs to ensure compliance.
Tax rules, limits and rates change. Confirm current figures with the IRS or your accountant before you file.
Regulatory Landscape for Compounded Medications
The USP <795> governs non-sterile compounded formulations like capsules, creams, and oral liquids, including requirements for beyond-use dating (BUD), ingredient quality, facility and equipment specifications, and documentation. The revised chapter became official on November 1, 2023, with updated BUD limits and new stability testing requirements. This means that compounding pharmacies must adhere to these regulations to ensure the quality and safety of their products.
In addition, 503A pharmacies must comply with the FDA's rule on compounded products that are essentially a copy of a commercially available drug, unless there is a documented clinical difference. This rule is crucial for ensuring that compounded GLP-1 medications are safe and effective.
The FDA has also taken action against telehealth companies for marketing compounded GLP-1 products without proper documentation. As a result, the FDA has issued warning letters to several companies, including 30 in March 2026 and 25 in June 2026. These letters emphasize the importance of complying with FDA regulations, including documenting clinical differences and ensuring that compounded products are safe and effective.
For example, California and Iowa have binding rules requiring documented clinical differences for compounded copies of approved drugs.

The rules in this guide
| Amount | Required | In Incurdesk |
|---|---|---|
| Above $50 | Itemised receipt | Checked on every expense |
| Above $150 | Written business purpose | Checked on every expense |
| Above $250 | Names of attendees | Checked on every expense |
| Above $2,500 | Senior sign-off; never auto-approved | Checked on every expense |
Each rule is checked on every expense by Incurdesk’s approval agent.
Limitations and Rates
,
- ,
- , ,
,
, , and . No headings, no markdown. The revised chapter also increased the minimum cleanroom classification for sterile compounding from Class A to Class B. This means that pharmacies must adhere to more stringent requirements for cleanroom design, garbing, and monitoring to prevent contamination. Additionally, output HTML only must be validated at regular intervals to ensure compliance with USP <797> INAbout IncurdeskAI expense management for finance teams and whoever keeps the books. It checks every expense against your rules, approves the routine ones and chases missing receipts for you.
Try it free for 30 days →Stop losing 4+ hours a week
30-day free trial · No credit card · Setup in 15 minutes
- ,